Nuvation Bio Inc. (NUVB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67080N1019
Nuvation Bio Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 62.90 m USD |
| Operating income | -213.06 m USD |
| EBIT | -190.95 m USD |
| Net income | -204.63 m USD |
| Diluted EPS – continuing operations | -0.60 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
More stocks
- Faes Farma SA (FAE.MC)
- Silvercorp Metals Inc (SVM.TO)
- Redcare Pharmacy NV (RDC.DE)
- Montea NV (MONT.BR)
- Flight Centre Travel Group Ltd (FLT.AX)
- QCR HOLDINGS INC (QCRH)
- WERNER ENTERPRISES INC (WERN)
- Sk Gas (018670.KS)
- Charter Hall Long Wale REIT (CLW.AX)
- National Bank Holdings Corp (NBHC)
- Doosan Fuel Cell Co Ltd (336260.KS)
- Alignment Healthcare, Inc. (ALHC)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.